Regulatory PathRegulatory requirements compared

Active substance

Latanoprostene bunod

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
VYZULTA0.024 %Eye drops, solution · Ophthalmic use1 BottleSAR 92.05NCE · PrescriptionBausch & Lomb, IncorporatedValid
Indications — CHI Daman Drug Formulary

OPEN ANGLE GLUCOMA

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
VYZULTA0.024%solution/drops · ophthalmicBAUSCH AND LOMBPrescription2 Nov 2017
LATANOPROSTENE BUNOD0.024%solution/drops · ophthalmicGLANDPrescription29 Apr 2025

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
VYZULTA024842180.024 % / W/VSOLUTION · OPHTHALMICBAUSCH & LOMB INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACVYZULTA 0.024% OPHTH SOLUTION$102.28986per ML23 Sep 2026
US NADACVYZULTA 0.024% OPHTH SOLUTION$102.25131per ML23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.